Clinical trial · Observational
Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter prospective observational cohort study in adults with hepatocellular carcinoma (HCC) without baseline extrahepatic metastasis who are receiving routine clinical management and follow-up at participating centers. The study evaluates the real-world implementation and clinical utility of a locked machine learning-guided risk stratification strategy for predicting lung and bone metastasis and supporting risk-stratified surveillance. The locked strategy uses prespecified 12-month risk thresholds and linked care pathways and is implemented without retraining or threshold revision. No study-mandated treatment or surveillance assignment is performed; clinical care remains at physician discretion according to local practice. The study assesses model transportability and calibration, implementation outcomes (including completion of prespecified actions, timeliness of action, and treatment activation), clinically actionable detection outcomes, patient-important outcomes, and longer-term survival. Comparative analyses use centre- and calendar-epoch-aligned usual-care episodes as the primary observational comparator.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Evaluation | — | UNRESOLVED | — |
| HCC - Hepatocellular Carcinoma | Hepatocellular Carcinoma | PROBABILISTIC | 0.70 |
| Machine Learning | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Machine Learning-Based Risk Assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Prospective Observational Cohort
- description
- Adults with hepatocellular carcinoma without baseline extrahepatic metastasis enrolled in a prospective observational cohort to evaluate a locked machine learning-guided risk stratification strategy for predicting lung and bone metastasis and supporting risk-stratified surveillance in routine practice. No experimental interventions are assigned, and clinical management remains at physician discretion.
- interventionNames
- Other: Machine Learning-Based Risk Assessment
Primary outcomes (1)
- measure
- Completion of a Prespecified Pathway-Concordant Action Within 60 Days
- timeFrame
- Day 0 to day 60 after the eligible index assessment.
- description
- Proportion of eligible index episodes with completion of at least one prespecified pathway-concordant action within 60 days after the eligible index assessment. A pathway-concordant action was defined as SOP-concordant multidisciplinary team review, escalated lung- or bone-metastasis-directed imaging, or referral.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Diagnosis of hepatocellular carcinoma (HCC) confirmed by histopathology or accepted radiologic criteria per international guidelines. * No evidence of extrahepatic metastasis at baseline evaluation. * Receiving standard-of-care management with planned longitudinal follow-up in routine clinical practice. * Availability of baseline clinical and imaging data required for risk assessment using the pre-specified machine learning model. * Ability to provide written informed consent, or inclusion under ethics committee-approved procedures. Exclusion Criteria: * Confirmed extrahepatic metastasis at enrollment (baseline). * History of other active malignancy within the past 5 years, except adequately treated non-melanoma skin cancer or in situ carcinoma. * Incomplete baseline clinical information that precludes model-based risk assessment. * Expected survival \< 3 months due to severe comorbidities. * Participation in an interventional clinical trial that may substantially alter follow-up strategy or metastasis assessment.
References
Publications (0)
Data not yet available